source
- GSK presents promising late-stage lung cancer data from two investigational drugsGSK highlighted late-stage results for two of its lung cancer candidates, reporting encouraging efficacy signals that could advance the programs toward regulatory review. The company shared the da…
- Definium’s LSD therapy cuts anxiety scores in second late-stage trialDefinium Therapeutics reported that its LSD-based drug DT120 reduced anxiety symptoms in a second late-stage study. In the 12-week trial, patients receiving a 100-microgram dose saw an average 9.8…